RNA has recently emerged as an important nanotechnology platform due to its extraordinary diversity in structure and function. Small interfering RNA (siRNA), showed significant potential in new molecular approaches to down-regulate specific gene expression in mammalian cells. In fact, targeted gene suppression by antisense DNA and siRNA has shown promising preclinical results, and/or is currently in clinical trials for a variety of diseases, including many forms of cancer (e.g., melanoma, neuroblastoma, and pancreatic adenocarcinoma), genetic disorders, and macular generation . Despite the high therapeutic potential of siRNA, its application for clinical medicine is still limited mainly due to the lack of appropriate delivery systems. In such a situation, the development of clinically suitable, safe, and effective drug-delivery biomaterials are required for the widespread use of siRNA therapeutics for disease treatment. OMICS group publishes articles involving many subjects like Pharmacy, Life sciences, Engineering, Medical, Management and Clinical. Each of the above mentioned department publishes all the major kinds of articles which include; research, review, mini-review, short communication, case report etc.
Last date updated on July, 2014